Source: Health Canada shortage reports · Updated Oct 27, 2026
Glycopyrrolate has no current shortage reported in Canada. It has been in shortage before; the history is below.
An anticholinergic used to reduce saliva and airway secretions and, in inhalers, to treat COPD.
Products affected
0 / 7
Reports on file
26
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Resolved
GLYCOPYRROLATE INJECTION
0.2MG · LIQUID · OMEGA LABORATORIES LIMITED
DIN 02382857 · ended Sep 3, 2026 · Disruption of the manufacture of the drug.
Resolved
GLYCOPYRROLATE INJECTION USP
4MG · SOLUTION · STERIMAX INC
DIN 02473887 · ended May 27, 2026 · Delay in shipping of the drug.
Resolved
GLYCOPYRROLATE INJECTION USP
0.2MG · SOLUTION · JAMP PHARMA CORPORATION
DIN 02532379 · ended Apr 10, 2026 · Disruption of the manufacture of the drug.
Resolved
GLYCOPYRROLATE INJECTION USP
0.2MG · SOLUTION · SANDOZ CANADA INCORPORATED
DIN 02039508 · ended Mar 30, 2026 · Demand increase for the drug.
Resolved
GLYCOPYRROLATE INJECTION USP
0.4MG · SOLUTION · STERIMAX INC
DIN 02473895 · ended Mar 11, 2026 · Demand increase for the drug.
Resolved
GLYCOPYRROLATE INJECTION USP
0.2MG · SOLUTION · STERIMAX INC
DIN 02473879 · ended Mar 11, 2026 · Delay in shipping of the drug.
Resolved
GLYCOPYRROLATE INJECTION
0.2MG · LIQUID · OMEGA LABORATORIES LIMITED
DIN 02382857 · ended Feb 17, 2026 · Demand increase for the drug.
Resolved
GLYCOPYRROLATE INJECTION
0.2MG · LIQUID · OMEGA LABORATORIES LIMITED
DIN 02382857 · ended Nov 8, 2025 · Demand increase for the drug.
Resolved
GLYCOPYRROLATE INJECTION USP
0.4MG · SOLUTION · STERIMAX INC
DIN 02473895 · ended Sep 15, 2025 · Requirements related to complying with good manufacturing practices.
Resolved
GLYCOPYRROLATE INJECTION USP
4MG · SOLUTION · STERIMAX INC
DIN 02473887 · ended Sep 15, 2025 · Requirements related to complying with good manufacturing practices.
Resolved
GLYCOPYRROLATE INJECTION
0.2MG · LIQUID · OMEGA LABORATORIES LIMITED
DIN 02382857 · ended Jul 31, 2025 · Delay in shipping of the drug.
Resolved
GLYCOPYRROLATE INJECTION USP
0.2MG · SOLUTION · SANDOZ CANADA INCORPORATED
DIN 02039508 · ended Dec 4, 2023 · Disruption of the manufacture of the drug.
Showing 12 of 26 reports. All reports are on file with Health Canada.
What's happening
There are no active shortage reports for Glycopyrrolate. Health Canada has 26 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.
Glycopyrrolate is classified under “DRUGS FOR FUNCTIONAL BOWEL DISORDERS” (ATC A03AB).
Recent changes
Oct 27, 2026
Shortage resolved
Sep 2, 2026
Estimated end date pushed back : Aug 31, 2026 → Sep 4, 2026
Aug 12, 2026
Estimated end date pushed back : Aug 24, 2026 → Aug 31, 2026
Jul 29, 2026
Estimated end date pushed back : Aug 21, 2026 → Aug 24, 2026
Common questions
What is Glycopyrrolate used for?
An anticholinergic used to reduce saliva and airway secretions and, in inhalers, to treat COPD.
When will Glycopyrrolate be back in stock in Canada?
Glycopyrrolate has no active shortage; supply is normal per Health Canada reports.
Why is Glycopyrrolate in shortage?
It isn't currently. Past reports and their reasons are listed above.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.